These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34559937)

  • 1. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor?
    Essam R; Ehab R; Al-Razzaz R; Khater MW; Moustafa EA
    J Cosmet Dermatol; 2021 Dec; 20(12):3727-3729. PubMed ID: 34559937
    [No Abstract]   [Full Text] [Related]  

  • 2. New-onset systemic lupus erythematosus after ChAdOX1 nCoV-19 and alopecia areata after BNT162b2 vaccination against SARS-CoV-2.
    Gamonal SBL; Marques NCV; Pereira HMB; Gamonal ACC
    Dermatol Ther; 2022 Sep; 35(9):e15677. PubMed ID: 35770484
    [No Abstract]   [Full Text] [Related]  

  • 3. Alopecia areata following ChAdOx1 nCoV-19 vaccination (Oxford/AstraZeneca).
    Su HA; Juan CK; Chen YC
    J Formos Med Assoc; 2022 Oct; 121(10):2138-2140. PubMed ID: 35379574
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrence of alopecia areata after covid-19 vaccination: A report of three cases in Italy.
    Rossi A; Magri F; Michelini S; Caro G; Di Fraia M; Fortuna MC; Pellacani G; Carlesimo M
    J Cosmet Dermatol; 2021 Dec; 20(12):3753-3757. PubMed ID: 34741583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alopecia areata not due by isotretinoin. A thought in COVID-19 time.
    Rodríguez-Jiménez P; Ramirez-Bellver JL; Ruiz-Rodríguez R
    Dermatol Ther; 2020 Jul; 33(4):e13451. PubMed ID: 32323454
    [No Abstract]   [Full Text] [Related]  

  • 6. Oxford-AstraZeneca ChAdOx1 COVID-19 Vaccine Does Not Alter Platelet Aggregation.
    Limami Y; Khalki L; Zaid N; Khyatti M; Turk JE; Ammara M; Mtairag EM; Oudghiri M; Naya A; Taberkant M; Zaid Y
    Semin Thromb Hemost; 2022 Feb; 48(1):109-111. PubMed ID: 33971677
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
    Youssef S; Lavian J; Lee EY; Fan W; Bordone LA
    J Am Acad Dermatol; 2023 May; 88(5):1125-1127. PubMed ID: 35551958
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alopecia areata following COVID-19 vaccine: a systematic review.
    Zhu Y; Ouyang X; Zhang D; Wang X; Wu L; Yu S; Tan Y; Li W; Li C
    Eur J Med Res; 2024 Jul; 29(1):356. PubMed ID: 38970130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
    Žagar T; Hlača N; Brajac I; Prpić-Massari L; Peternel S; Kaštelan M
    Br J Dermatol; 2022 Mar; 186(3):e110. PubMed ID: 34817862
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen.
    Soltani Hekmat A; Javanmardi K
    Biomed Res Int; 2021; 2021():7702863. PubMed ID: 34734086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine.
    Awada B; Abdullah L; Kurban M; Abbas O
    J Cosmet Dermatol; 2022 Mar; 21(3):883-885. PubMed ID: 34997985
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
    Sønderskov KM; Dinesen PT; Østergaard SD
    Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC29. PubMed ID: 33646835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of SARS-CoV-2 infection and its vaccines in various types of hair loss.
    Aryanian Z; Balighi K; Hatami P; Afshar ZM; Mohandesi NA
    Dermatol Ther; 2022 Jun; 35(6):e15433. PubMed ID: 35266262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination.
    Crane P; Wong C; Mehta N; Barlis P
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34625447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
    Aşkın Ö; Özkoca D; Uzunçakmak TK; Serdaroğlu S
    Dermatol Ther; 2021 Mar; 34(2):e14746. PubMed ID: 33405372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222).
    Ho JD; McNish A; McDonald L; Burrell C; Smith-Matthews S
    JAAD Case Rep; 2022 Jul; 25():4-8. PubMed ID: 35642187
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2.
    Tølbøll Sørensen AL; Rolland M; Hartmann J; Harboe ZB; Roed C; Jensen TØ; Kolte L; El Fassi D; Hillingsø J; Radziwon-Balicka A; Soyka RS; Hansen K; Kirkby N; Goetze JP; Gybel-Brask M; Leinøe EB; Hvas AM; Kampmann P; Stensballe J
    Blood Adv; 2021 Jun; 5(12):2569-2574. PubMed ID: 34137813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.